Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2025 and 2024, were as follows (in thousands):

	Three Months Ended						Three Months Ended
	June 30, 2025						June 30, 2024
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	364,025	$	18,437	$	382,462	$	327,815	$	10,188	$	338,003
Cost of sales standard(1)		147,710		4,342				140,492		3,256
Cost of sales other(2)		43,949		1,974				32,828		327
Selling, general and administrative expenses		107,673		5,424				91,634		2,951
Research and development expenses		23,306		1,061				19,643		620
Other operating expenses(3)		143		—				306		—
Income from operations	$	41,244	$	5,636	$	46,880	$	42,912	$	3,034	$	45,946
Total other expense — net						(3,501)						(103)
Income before income taxes					$	43,379					$	45,843

	Six Months Ended						Six Months Ended
	June 30, 2025						June 30, 2024
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	702,738	$	35,075	$	737,813	$	641,189	$	20,322	$	661,511
Cost of sales standard(1)		286,151		8,705				273,558		6,365
Cost of sales other(2)		81,732		4,718				68,130		643
Selling, general and administrative expenses		208,647		11,936				182,934		6,079
Research and development expenses		45,260		1,585				40,559		1,186
Other operating expenses(3)		1,166		—				189		—
Income from operations	$	79,782	$	8,131	$	87,913	$	75,819	$	6,049	$	81,868
Total other expense — net						(6,576)						(1,677)
Income before income taxes					$	81,337					$	80,191

(1) Cost of sales standard represents costs of goods sold measured at the internal standard cost for production of inventory. Inventory standard costs include material, labor and manufacturing overhead.

(2) Cost of sales other for all segments includes amortization expense associated with our developed technology and license agreement intangible assets, freight and handling associated with shipments to customers, provisions based on estimated excess, slow moving and obsolete inventories, manufacturing and price variances, and royalties.

(3) Other operating expenses include contingent consideration expense (benefit) related to the changes in fair value of contingent payments associated with acquisitions.

Total depreciation and amortization by operating segment for the three and six-month periods ended June 30, 2025 and 2024, consisted of the following (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2025		2024		2025		2024
Cardiovascular	$	28,767	$	23,964	$	55,737	$	47,352
Endoscopy		2,254		127		4,576		338
Total	$	31,021	$	24,091	$	60,313	$	47,690